Ioana Andreica

Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial

Nils Venhoff, Wolfgang Schmidt, Raoul Bergner et al. · The Lancet Rheumatology · 2023 · 89 citations

Life Sciences, Immunology, Pharmacotherapy +12

SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study

David Saadoun, Matheus Vieira, Mathieu Vautier et al. · The Lancet Rheumatology · 2021 · 40 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study

Uta Kiltz, Aylin Celik, Styliani Tsiami et al. · RMD Open · 2021 · 22 citations · Full text

Medicine, Immunology, Infectious Diseases +12

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination

Ioana Andreica, Arturo Blazquez‐Navarro, Jan Sokolar et al. · RMD Open · 2022 · 20 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry

Jasmin Kuemmerle‐Deschner, Tilmann Kallinich, Jörg Henes et al. · RMD Open · 2024 · 16 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17